A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors Meeting Abstract
| Authors: | Twelves, C. J.; Banerji, U.; Tap, W. D.; Cook, N.; Evans, T. R. J.; Plummer, R.; Anthoney, A.; Plummer, C.; Dawson, R.; Loadman, P.; Lahu, G.; Jones, H.; Kinnersley, N.; Edwards, R.; Gordon, G.; Cranmer, L. D. |
| Abstract Title: | A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sept 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S511 |
| Language: | English |
| ACCESSION: | WOS:001326612900639 |
| DOI: | 10.1016/j.annonc.2024.08.712 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 646P -- Source: Wos |
